GlassScriptPhysician profile
Hajin Lim
NPI 1457324592
$4,294.74
in general payments reported to CMS, 2019-2025
35 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $160 · 2021: $734 · 2022: $718 · 2023: $880 · 2024: $741 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $838.35 | 2019-2025 | Cardiomems, Proclaim |
| Novartis Pharmaceuticals Corporation | $636.38 | 2019-2025 | |
| Boston Scientific Corporation | $534.72 | 2021-2025 | Watchman Flx, Watchman Access System, Resonate El Icd Vr |
| Amgen INC. | $264.00 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $218.97 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $186.77 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $177.90 | 2021-2024 | Andexxa, Brilinta |
| Impulse Dynamics (USA) INC. | $149.98 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $148.94 | 2019-2024 | Xarelto |
| Abiomed | $143.94 | 2019 | |
| Biotronik INC. | $137.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.64 | 2021-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $82.62 | 2023-2024 | Opsumit, Uptravi |
| Medtronic, INC. | $65.64 | 2021-2025 | Avalus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.61 | 2023-2025 | Lifevest |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $56.05 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.24 | 2025 | |
| Imperative Care, INC | $43.85 | 2025 | Symphony Catheter |
| Kestra Medical Technology Services, INC. | $38.31 | 2025 | Assure Wcd |
| Tactile Systems Technology INC | $37.16 | 2019 | |
| Esperion Therapeutics, INC. | $36.84 | 2021 | |
| Alnylam Pharmaceuticals INC. | $34.04 | 2025 | |
| Amarin Pharma, INC. | $33.27 | 2019-2022 | |
| Inari Medical, INC. | $29.96 | 2022 | |
| Baxter Healthcare | $29.86 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Shockwave Medical, INC | $24.38 | 2022 | |
| Irhythm Technologies, INC. | $24.27 | 2024 | Zio Xt Patch, Zio Monitor |
| Angiodynamics, INC. | $23.05 | 2025 | Alphavac |
| Medicomp INC | $18.74 | 2024 | Telepatch Cardiac Monitor |
| Cvrx, INC. | $17.28 | 2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $16.59 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $15.92 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $13.35 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $10.80 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hajin Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.